Zacharieva S, Orbetzova M, Tcharaktchiev D, Angelova-Gateva P, Andonova K
Clinical Center of Endocrinology and Gerontology, Sofia, Bulgaria.
Methods Find Exp Clin Pharmacol. 1995 Nov;17(9):615-9.
Twelve healthy subjects were studied after single dose (200 mg p.o.) and 3 days (2 x 200 mg daily p.o.) indobufen treatment. Our findings indicated that in addition to well-known antiaggregant activity, indobufen significantly decreases thromboxane B2 and increases 6-keto-prostaglandin F1 after acute and short-term treatment. The activity of renin-angiotensin-aldosterone system and kallikrein-kinin system did not change significantly after both experimental periods. It seems also unlikely that atrial natriuretic peptide mediates the effects of the drug.
对12名健康受试者进行了研究,分别给予单剂量(口服200毫克)和3天(每日口服2次,每次200毫克)吲哚布芬治疗。我们的研究结果表明,除了众所周知的抗聚集活性外,吲哚布芬在急性和短期治疗后可显著降低血栓素B2并增加6-酮-前列腺素F1。在两个实验阶段后,肾素-血管紧张素-醛固酮系统和激肽释放酶-激肽系统的活性均未发生显著变化。心房利钠肽似乎也不太可能介导该药物的作用。